Medical management of Crohn's disease: current therapy and recent advances

References

• Liptay S, Fulda S, Schanbacher M et al. Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br. J. Pharmacol. 137, 608–620 (2002).
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT Jr et al. National Co-operative Crohn’s Disease Study: results of drug treatment. Gastroenterology 77, 847–869 (1979).
   PubMed Web of Science ®Google Scholar
• Van Hees PA, Van Lier HJ, Van Elteren PH et al. Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut 22, 404–409 (1981).
   PubMedGoogle Scholar
• Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig. Dis. Sci. 28, 833–842 (1983).
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med. 289, 491–495 (1973).
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 41, 209–214 (1997).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Lofberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N. Engl. J. Med. 331, 842–845 (1994).
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med. 331, 836–841 (1994).
   PubMed Web of Science ®Google Scholar
• Bar-Meir S, Chowers Y, Lavy A et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 115, 835–840 (1998).
   PubMed Web of Science ®Google Scholar
• Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther. 14, 1419–1428 (2000).
   PubMed Web of Science ®Google Scholar
• Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn’s disease. Aliment. Pharmacol. Ther. 16, 1509–1517 (2002).
   PubMed Web of Science ®Google Scholar
• Thomsen OO, Cortot A, Jewell D et al. comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N. Engl. J. Med. 339, 370–374 (1998).
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302, 981–987 (1980).
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double-blind study of azathioprine in the management of Crohn’s disease. Gut 37, 674–678 (1995).
   PubMed Web of Science ®Google Scholar
• Ewe K, Press AG, Singe CC et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105, 367–372 (1993).
   PubMed Web of Science ®Google Scholar
• Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology 66, 916–922 (1974).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst. Rev. CD000545 (2000).
   Google Scholar
• Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081–1085 (1993).
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115, 813–821 (1998).
   PubMed Web of Science ®Google Scholar
• Daniel F, Cadranel JF, Seksik P et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol. Clin. Biol. 29, 600–603 (2005).
   PubMedGoogle Scholar
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91, 854–862 (2001).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am. J. Gastroenterol. 95, 2308–2312 (2000).
   PubMed Web of Science ®Google Scholar
• Connel WR, Kamm MA, Dickson M et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343, 1249–1252 (1994).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118, 1018–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami H-O. Extracolonic malignancies in inflammatory bowel disease. Cancer 67, 2015–2019 (1991).
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Olsen JH, Frisch M, Johanssen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int. J. Cancer. 60, 330–333 (1995).
   PubMed Web of Science ®Google Scholar
• Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124, 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Alstead EM, Ritchie JK, Lennard-Jones JE et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99, 443–446 (1990).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med. 332, 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst. Rev. CD003459 (2005).
   PubMedGoogle Scholar
• Kurnik D, Loebstein R, Fishbein E et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 18, 57–63 (2003).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study. Dig. Liver Dis. 35, 619–627 (2003).
   PubMedGoogle Scholar
• Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 95, 3150–3156 (2000).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J. Rheumatol. 20, 1121–1125 (1993).
   PubMed Web of Science ®Google Scholar
• Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J. Rheumatol. 14, 1164–1171 (1987).
   PubMed Web of Science ®Google Scholar
• Kozarek RA, Bredfeldt JE, Rosoff LE et al. Does chronic methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? Gastroenterology 100, A221 (1991).
   Google Scholar
• Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a 48 week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 44, 1515–1524 (2001).
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW et al. European Co-operative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86, 249–266 (1984).
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. CD000301 (2003).
   PubMedGoogle Scholar
• Lichstenstein GR, Cohen RD, Feagan BG et al. Safety of infliximab and other Crohn’s diseae therapies – Updated Treat registry data with over 10,000 patient-years of follow-up. Digestive Disease Week. W1034, Chicago, IL, USA, 14–19 (2005).
   Google Scholar
• Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124, 1774–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, Dahlerup JF, Baatrup G. Complement activation in plasma before and after infliximab treatment in Crohn’s disease. Scand. J. Gastroenterol. 38, 1050–1054 (2003).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 337, 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol. 99, 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Zachos M. Tumor necrosis factor-α antibody for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. CD003574 (2004).
   PubMedGoogle Scholar
• Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn’s disease: optimize not immunize. Gastroenterology 124, 1140–1145 (2003).
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98, 1315–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Baert F, Norman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm. Rep. 52, 1–77 (2003); Published correction appears in MMWR Recomm. Rep. 53, 1203 (2005).
   PubMedGoogle Scholar
• Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol. 2, 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the antiTNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
   PubMed Web of Science ®Google Scholar
• Infliximab drug information. Centocor, Inc., Horsham, PA, USA (2005).
   Google Scholar
• Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 117, 1433–1437 (1999).
   PubMed Web of Science ®Google Scholar
• Crohn's Therapy Resource Evaluation and Assessment Tool (TREAT) Registry. Centocor, Inc., Horsham, PA, USA (2004).
   Google Scholar
• Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology 123, 33–40 (2002).
   PubMed Web of Science ®Google Scholar
• Sutherland L, Singleton J, Sessions J et al. Double-blind, placebo-controlled trial of metronidazole in Crohn’s disease. Gut 32, 1071–1075 (1991).
   PubMed Web of Science ®Google Scholar
• Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm. Bowel Dis. 8, 10–15 (2002).
   PubMed Web of Science ®Google Scholar
• Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. 91, 328–332 (1996).
   PubMed Web of Science ®Google Scholar
• Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr. Med. Res. Opin. 21, 1165–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 31, 453–457 (2000).
   PubMed Web of Science ®Google Scholar
• Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 4, 5 (2004).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124, 1202–1209 (2003).
   PubMed Web of Science ®Google Scholar
• Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand. J. Gastroenterol. 22, 877–883 (1987).
   PubMed Web of Science ®Google Scholar
• Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion 45, 88–92 (1990).
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J. Clin. Gastroenterol. 19, 278–282 (1994).
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer SB, Gitnick GL et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology 104, 1293–1301 (1993).
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn’s disease. Dig. Dis. Sci. 40, 931–935 (1995).
   PubMedGoogle Scholar
• Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2, 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol. 2, 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302, 981–987 (1980).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 119, 895–902 (2000).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127, 723–729 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst. Rev. CD000067 (2000).
   Google Scholar
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 123, 132–142 (1995).
   PubMed Web of Science ®Google Scholar
• Vilien M, Dahlerup JF, Munck LK, Norregaard P, Gronbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year. Aliment Pharmacol Ther. 19, 1147–1152 (2004).
   PubMedGoogle Scholar
• O’Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 2, 955–957 (1978).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Nion-Larmurier I, Beaugerie L et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54, 237–241 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn’s Study Group Investigators. N. Engl. J. Med. 342, 1627–1632 (2000).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment. Pharmacol. Ther. 21, 363–371 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am. J. Gastroenterol. 100, 1780–1787 (2000).
   Google Scholar
• Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108, 1617–1621 (1995).
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83, 383–387 (1982).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128, 856–861 (2005).
   PubMed Web of Science ®Google Scholar
• Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44, 625–628 (1999).
   PubMed Web of Science ®Google Scholar
• Fellermann K, Steffen M, Stein J et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 171–176 (2000).
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113, 1465–1473 (1997).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn’s disease remains uncertain. Gastroenterology 127, 990–993 (2004).
   PubMed Web of Science ®Google Scholar
• Lochs H, Mayer M, Fleig WE et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Co-operative Crohn’s Disease Study VI. Gastroenterology 118, 264–273 (2000).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst. Rev. CD003715 (2005).
   PubMedGoogle Scholar
• Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. CD000301 (2003).
   PubMedGoogle Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 52, 405–409 (2002).
   Google Scholar
• Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Co-operative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77, 914–920 (1979).
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Loftus EV Jr, Tremaine WJ et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122, 875–880 (2002).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. 350, 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. 340, 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Lecomte T, Contou JF, Beaugerie L et al. Predictive factors of response of perianal Crohn’s disease to azathioprine or 6-mercaptopurine. Dis. Colon Rectum. 46, 1469–1475 (2003).
   PubMedGoogle Scholar
• Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 125, 380–388 (2003).
   PubMed Web of Science ®Google Scholar
• Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment. Pharmacol. Ther. 19, 295–301 (2004).
   PubMedGoogle Scholar
• Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: a case series. Aliment. Pharmacol. Ther. 18, 1003–1008 (2003).
   PubMed Web of Science ®Google Scholar
• Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment. Pharmacol. Ther. 18, 1113–1120 (2003).
   PubMed Web of Science ®Google Scholar
• West RL, van der Woude CJ, Hansen BE et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 20, 1329–1336 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 79, 357–365 (1980).
   PubMed Web of Science ®Google Scholar
• Dieckgraefe BK, Korzenik JR. Treatment of active Crohn’s disease with recombinant human granulocyte–macrophage colony-stimulating factor. Lancet 360, 1478–1480 (2002).
   PubMed Web of Science ®Google Scholar
• Korzenik JR, Dieckgraefe BK, Valentine JF et al. Sargramostim for active Crohn’s disease. N. Engl. J. Med. 352, 2193–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human antiTNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol. 99, 1984–1989 (2004).
   PubMed Web of Science ®Google Scholar
• Youdim A, Vasiliauskas EA, Targan SR et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. 10, 333–338 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Lukas M, MacIntosh D, Rutgeerts P, Sandborn W, Pollack P. A randomized, double-blind, placebo-controlled trial of the human antiTNF – a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease. Digestive Disease Week. New Orleans, LA, USA, 15–20 (2004).
   Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB et al. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120, 1330–1338 (2001).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129, 807–818 (2005).
   PubMed Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther. 20, 1337–1346 (2004).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan B, Radford-Smith G, Kovacs A, Enns R, Patel J. A randomized placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn’s disease. Gastroenterology 124, A469 (2003).
   Google Scholar
• Schreiber S et al. Certolizumab pegol, a humanised antiTNF PEGylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a Phase III study (PRECiSE). 13th United European Gastroenterology Week. Copenhagen, Denmark, 15–19 October (2005).
   Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 12, 1088–1094 (2001).
   Google Scholar
• Gordon FH, Lai CW, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology 121, 268–274 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med. 348, 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 353, 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353, 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353, 369–374 (2005).
   PubMed Web of Science ®Google Scholar
• Hommes D, Mikhajlova T, Stoinov S et al. Fontolizumab (HuZAF™), a humanized antiIFN-γ antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease (CD). Digestive Disease Week. New Orleans, LA, USA, 15–20 May (2004).
   Google Scholar
• de Villiers WJ, Katz S, Salzberg BA et al. Chronic dosing of fontolizumab (huzaftm), a humanized antiIFN-γ antibody, in patients with moderate to severe Crohn’s disease (CD). Gastroenterology 128 (Suppl. 2), A-111 (2005).
   Google Scholar
• Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 102, 514–519 (1992).
   PubMed Web of Science ®Google Scholar
• Hosokawa T, Kusugami K, Ina K et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14, 987–996 (1999).
   Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761–1769 (2004).
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818–825 (2005).
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126, 989–996 (2004).
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med. 351, 2069–2079 (2004).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003).
   PubMed Web of Science ®Google Scholar
• Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG. Leflunomide treatment of Crohn’s disease patients intolerant to standard immunomodulator therapy. J. Clin. Gastroenterol. 37, 125–128 (2003).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Hassard PV, Seidman EG et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7, 181–189 (2001).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Vasiliauskas EA, Singh H et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125, 298–303 (2003).
   PubMed Web of Science ®Google Scholar
• Lerebours E, Bussel A, Modigliani R et al. Treatment of Crohn’s disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 107, 357–361 (1994).
   PubMed Web of Science ®Google Scholar
• Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn’s disease. J. Clin. Gastroenterol. 19, 202–205 (1994).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Mathieu D, Bouault JM et al. Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis. Colon Rectum. 38, 609–614 (1995).
   PubMedGoogle Scholar
• Hommes D, Baert F, van Assche C et al. Management of recent onset Crohn’s disease – a controlled randomized trial comparing step-up and top-down therapy. Digestive Disease Week. Chicago, IL, USA, 14–19 May 2005.
   Google Scholar